|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 156 JPY | -4.29% |
|
-4.29% | -36.84% |
SymBio Pharmaceuticals Limited provided earnings guidance for the Fiscal Year 2023. For the year, the company now expects Net Sales to be JPY 5,603 million compared to JPY 6,477 million. Operating loss to be JPY 680 million compared to JPY 331 million.
Loss attributable to owner of parent to be JPY 1,291 million compared to JPY 370 million. Loss per share to be JPY 32.53 per share compared to JPY 9.34 per share previously forecasted.
| 1st Jan change | Capi. | |
|---|---|---|
| -36.84% | 48.22M | |
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B |
SYMBIO PHARMACEUTICALS LIMITED 
